Immatics/$IMTX

1D1W1MYTD1Y5YMAX

About Immatics

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Ticker
$IMTX
Sector
Health
Primary listing
NASDAQ
Employees
704
Headquarters
Tübingen, Germany
Website
www.immatics.com

Immatics Metrics

BasicAdvanced
$1.2B
-
-$1.84
1.32
-

What the Analysts think about Immatics

Analyst ratings (Buy, Hold, Sell) for Immatics stock.
Analyst projections of the future price of Immatics stock.

Bulls say / Bears say

Anzu-cel’s updated Phase 1b melanoma data showed a 56% confirmed response rate, 14.6 months’ median duration of response and 16.2 months’ median overall survival, with a predictable and manageable safety profile. The Phase 3 SUPRAME trial remains on track for topline progression-free-survival data in the first half of 2027 and a planned regulatory filing later that year. (BioSpace)
Immatics is building more than a single-drug story. IMA203CD8 has shown activity across difficult gynaecological cancers and synovial sarcoma, while the MAGEA4/8 bispecific IMA401 has shown encouraging activity in head and neck and lung cancers, supporting several possible routes to expand beyond melanoma. (BioSpace, BioSpace)
The company reported $448.2 million of cash and financial assets at 30 June 2026 and projected its cash reach into 2028, giving it time to reach the pivotal readout. Its subsequent $150 million equity offering adds further funding, while Moderna’s first patient dosing in a partnered trial triggered a milestone payment and supports the value of Immatics’ target-discovery platform. (BioSpace, Immatics)
The expected 2026 interim PFS checkpoint for SUPRAME has been removed because progression and death events are occurring more slowly than originally modelled. Investors now face a largely binary efficacy readout in the first half of 2027, leaving longer for sentiment and valuation to depend on unproven results. (BioSpace, Biotech Distilled)
Immatics remains heavily loss-making and is spending aggressively: first-half 2026 net loss was €120.3 million and research and development costs were €121.6 million. The $150 million share and warrant offering strengthens the balance sheet but dilutes existing holders and shows that further funding remains part of the investment case. (StockTitan, Immatics)
The pipeline beyond anzu-cel is still early-stage, so encouraging initial activity has not yet established commercial efficacy. IMA401 remains in Phase 1 and the first data from its combination with IMA402 are not expected until 2027, leaving the company highly exposed to the outcome of the melanoma programme. (BioSpace, BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.

Immatics Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Immatics Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.